207_Combined course Presentations

Take Home Message (Advanced Stage HL)

 To date, waiting for definitive results of randomised studies (HD0607 and GD0801) patients treated with ABVD x 6 should receive consolidative ISRT to bulky site at baseline

 Patients treated with more intensive chemotherapy ( BEACOPPescalated x 6) need additional RT only to PET+ residual disease according to GHSG HD15.

 Patients with residual focal lesions after chemotherapy should be considered for a sequential ISRT , with no regard to the chemotherapy schedule adopted (ABVD or BEACOPP)

 Multidisciplinary discussion is strongly recommended to offer the best treatment solution to each patient